To test this, we treated naive and resistant Trp53/Pten−/− GBM cells with the Kif15 inhibitor Kif15-IN-1 and allowed cell proliferation to continue for 72 h before measuring viable cell content. This evidence concerns the gene KIF15 and glioblastoma.